AU2018266690A1 - Biodegradable microparticles for sustained delivery of anti-angiogenic peptide - Google Patents

Biodegradable microparticles for sustained delivery of anti-angiogenic peptide Download PDF

Info

Publication number
AU2018266690A1
AU2018266690A1 AU2018266690A AU2018266690A AU2018266690A1 AU 2018266690 A1 AU2018266690 A1 AU 2018266690A1 AU 2018266690 A AU2018266690 A AU 2018266690A AU 2018266690 A AU2018266690 A AU 2018266690A AU 2018266690 A1 AU2018266690 A1 AU 2018266690A1
Authority
AU
Australia
Prior art keywords
present
microparticle
angiogenic peptide
sustained delivery
biodegradable microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018266690A
Other languages
English (en)
Inventor
Peter A. Campochiaro
Jordan J. Green
Jayoung Kim
Raquel LIMA E. SILVA
Adam MIRANDO
Niranjan Pandey
Aleksander S. Popel
Ron SHMUELI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Asclepix Therapeutics Inc
Original Assignee
Johns Hopkins University
Asclepix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Asclepix Therapeutics Inc filed Critical Johns Hopkins University
Publication of AU2018266690A1 publication Critical patent/AU2018266690A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2018266690A 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide Abandoned AU2018266690A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502913P 2017-05-08 2017-05-08
US62/502,913 2017-05-08
PCT/US2018/031663 WO2018208829A1 (en) 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide

Publications (1)

Publication Number Publication Date
AU2018266690A1 true AU2018266690A1 (en) 2019-12-12

Family

ID=64104968

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018266690A Abandoned AU2018266690A1 (en) 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide

Country Status (8)

Country Link
US (1) US20200179285A1 (https=)
EP (1) EP3621597A4 (https=)
JP (1) JP2020518651A (https=)
KR (1) KR20200003859A (https=)
CN (1) CN111315364A (https=)
AU (1) AU2018266690A1 (https=)
CA (1) CA3063140A1 (https=)
WO (1) WO2018208829A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021056B1 (pt) 2017-04-06 2022-11-22 Sustain Holdings, Llc Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
AU2020248438A1 (en) 2019-03-26 2021-10-28 Asclepix Therapeutics, Inc. Compositions and methods for treating ocular disease
EP3958889B1 (en) 2019-04-22 2025-01-08 Sustain Holdings, LLC Collagen mimetic peptide compositions for treating a posterior segment ocular disease or disorder involving the retina, retinal blood vessels, retinal nerves or optic nerve
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
US10314917B2 (en) * 2013-03-15 2019-06-11 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles
US9802984B2 (en) * 2013-06-07 2017-10-31 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
MX2019003895A (es) * 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.

Also Published As

Publication number Publication date
US20200179285A1 (en) 2020-06-11
WO2018208829A1 (en) 2018-11-15
KR20200003859A (ko) 2020-01-10
CA3063140A1 (en) 2018-11-15
WO2018208829A8 (en) 2019-07-04
JP2020518651A (ja) 2020-06-25
EP3621597A4 (en) 2021-06-02
EP3621597A1 (en) 2020-03-18
CN111315364A (zh) 2020-06-19

Similar Documents

Publication Publication Date Title
AU2018266690A1 (en) Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
NZ607797A (en) Corticosteroids for the treatment of joint pain
Motiei et al. Intrinsic parameters for the synthesis and tuned properties of amphiphilic chitosan drug delivery nanocarriers
IL292426B1 (en) Silk potein fragment compositions and articles manufactured therefrom
WO2011151356A3 (en) Methods for the preparation of injectable depot compositions
IL250652B2 (en) Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
WO2019075263A3 (en) Methods and compositions for topical delivery
EA201491185A1 (ru) Полимеры альфа-аминоамидинов и их применение
WO2016025394A3 (en) Delivery of bioactive, nanoencapsulated antioxidants
NZ629730A (en) Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
PH12017502155A1 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
JP2018500394A5 (https=)
WO2015110957A3 (en) Hybridosomes, compositions comprising the same, processes for their production and uses thereof
WO2019238610A8 (en) Keratin nanofibers as delivery vehicles of active ingredients, methods for the production and uses thereof
EA201170954A1 (ru) Фармацевтический или пищевой состав с контролируемым высвобождением и способ его получения
MX2018002627A (es) Metodo de cristalizacion y biodisponibilidad.
EP4548939A3 (en) Collagen-based therapeutic delivery systems
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
RU2012145811A (ru) Композиции и способы улучшенного удержания фармацевтической композиции на участке местного введения
PH12018500367A1 (en) Microparticle compositions comprising saflufenacil
BR112016025016A2 (pt) composições de proteína de partículas pequenas e métodos de produção
AU2017251957A1 (en) Hyaluronic acid conjugates and uses thereof
SA520412229B1 (ar) تركيبات صيدلية لها فترة إطلاق مُختارة
Tiash et al. Methotrexate-and cyclophosphamide-embedded pure and strontiumsubstituted carbonate apatite nanoparticles for augmentation of chemotherapeutic activities in breast cancer cells
EA201591111A1 (ru) Лекарственная дозированная форма, состоящая из полимерных частиц темозоломида

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period